Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 4/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.85 |
| ▸ | PRKACA | P17612 | 5/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303085 | 0.95 | WNT3A (0.90) | WNT3AROCK1PRKACAKMT2AMEN1 | |
| SCHEMBL13357346 | 0.91 | ROCK1 (1.00) | WNT3AROCK1PRKACAKMT2AMEN1 | |
| SCHEMBL13357345 | 0.91 | WNT3A (0.83) | WNT3AROCK1PRKACAKMT2AMEN1 | |
| SCHEMBL13357620 | 0.91 | WNT3A (0.83) | WNT3AROCK1PRKACAKMT2AMEN1 | |
| SCHEMBL13357604 | 0.91 | ROCK1 (1.00) | WNT3AROCK1PRKACAKMT2AMEN1 | |
| SCHEMBL13357587 | 0.88 | ROCK1 (1.00) | WNT3AROCK1PRKACAKMT2AMEN1 | |
| SCHEMBL1726119 | 0.87 | WNT3A (1.00) | WNT3AROCK1PRKACAKMT2AMEN1 | |
| SCHEMBL14102667 | 0.86 | KMT2A (1.00) | WNT3AROCK1PRKACAKMT2AMEN1 | |
| SCHEMBL19380614 | 0.83 | ELOVL1 (1.00) | WNT3AROCK1PRKACAKMT2AMEN1 | |
| SCHEMBL3257637 | 0.83 | ROCK1 (1.00) | WNT3AROCK1PRKACAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403832-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2012-01-11 | — | — | EP | claimed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | claimed |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2016-03-24 | — | — | US | disclosed |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2016-03-24 | — | — | US | disclosed |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2016-03-24 | — | — | US | disclosed |
| US-9238646-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators | NOVARTIS AG (CH) | 2016-01-19 | — | — | US | disclosed |
| US-9238646-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators | NOVARTIS AG (CH) | 2016-01-19 | — | — | US | disclosed |
| US-8546396-B2 | N-(hetero)aryl, 2-(hetero)aryl—substituted acetamides for use as Wnt signaling modulators | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8546396-B2 | N-(hetero)aryl, 2-(hetero)aryl—substituted acetamides for use as Wnt signaling modulators | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| EP-2623493-A1 | N-(hetero)aryl,2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators | IRM LLC (BM) | 2013-08-07 | — | — | EP | disclosed |
| EP-2403832-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2012-01-11 | — | — | EP | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | WNT3A 4/4885ROCK1 1223/4885PRKACA 2367/4885 |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | WNT1, CTNNB1, CTNNA1 | WNT3A 4/4885ROCK1 1223/4885PRKACA 2367/4885 |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | WNT3A 4/4885ROCK1 1223/4885PRKACA 2367/4885 |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, WNT3A | WNT3A 3/4885ROCK1 1489/4885PRKACA 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.